These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16327812)

  • 1. Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come.
    Rapoport AP
    Bone Marrow Transplant; 2006 Feb; 37(3):239-47. PubMed ID: 16327812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
    Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
    Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing immune responses for cancer therapy.
    Xue SA; Stauss HJ
    Cell Mol Immunol; 2007 Jun; 4(3):173-84. PubMed ID: 17601371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous white blood cell transfusion: toward a younger immunity.
    Charron D
    Hum Immunol; 2007 Oct; 68(10):805-12. PubMed ID: 17961768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
    Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-lymphocyte reconstitution following rigorously T-cell-depleted versus unmodified autologous stem cell transplants.
    Te Boekhorst PA; Lamers CH; Schipperus MR; Hintzen RQ; van der Holt B; Cornelissen JJ; Löwenberg B; Gratama JW
    Bone Marrow Transplant; 2006 Apr; 37(8):763-72. PubMed ID: 16518423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
    Rossi GR; Mautino MR; Awwad DZ; Husske K; Lejukole H; Koenigsfeld M; Ramsey WJ; Vahanian N; Link CJ
    J Immunother; 2008; 31(6):545-54. PubMed ID: 18528300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of dendritic cells in cancer immunotherapy.
    Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P
    Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cells.
    Wu S; Wang SQ; Zhang J; Tan XY; Liu JN
    Int J Oncol; 2006 Mar; 28(3):731-6. PubMed ID: 16465379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Making and circumventing tolerance to cancer.
    Kammertoens T; Blankenstein T
    Eur J Immunol; 2009 Sep; 39(9):2345-53. PubMed ID: 19634191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic MHC gene transfer enhances an effective antitumor immunity in the early period of autologous hematopoietic stem cell transplantation.
    Kobayashi A; Hara H; Ohashi M; Nishimoto T; Yoshida K; Ohkohchi N; Yoshida T; Aoki K
    Clin Cancer Res; 2007 Dec; 13(24):7469-79. PubMed ID: 18094431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulators of apoptosis: suitable targets for immune therapy of cancer.
    Andersen MH; Becker JC; Straten Pt
    Nat Rev Drug Discov; 2005 May; 4(5):399-409. PubMed ID: 15864269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI?
    Kennedy-Nasser AA; Bollard CM
    Bone Marrow Transplant; 2007 Jul; 40(2):93-104. PubMed ID: 17502898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation.
    Perruccio K; Topini F; Tosti A; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
    Blood Cells Mol Dis; 2008; 40(1):76-83. PubMed ID: 17977031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
    Fujii S
    Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy with dendritic cells for cancer.
    Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
    Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.